Evidence map›Paper›PMID 23558214›Full record

ArticleEye (London, England)2013

Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab.

K H Patel, C C Chow, R Rathod, W F Mieler, J I Lim, L J Ulanski, Y I Leiderman, V Arun, F Y Chau

Registry-linked trialOpen access · bronzeAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Eye (London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02246829 (Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept), which is not on this map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
14.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02246829 phase4completednot on this mapstarted 2014, after this paper: background citation

Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®) (2mg) Over a 12-week Period for Patients Suffering From Neovascular Age-related Macular Degeneration (AMD) French SD OCT in wAMD

TypeinterventionalSponsorUniversity Hospital, BordeauxRan2014 to 2015Enrolled50ConditionsNeovascular Age-related Macular Degeneration of All SubtypesArmsIntravitreal injection
3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 92 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. [Change of therapy from ranibizumab to aflibercept for recurrent or persistent exudative age-related macular degeneration].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2015
    Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

K H PatelDepartment of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Chicago, IL 60612, USA.
C C Chow
R Rathod
W F Mieler
J I Lim
L J Ulanski
Y I Leiderman
V Arun
F Y Chau
University of Illinois Chicago · US

Funding

UIC K12 Independent Clinical Vision Scientist Development ProgramK12EY021475 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI ALI R DJALILIAN, CHARLOTTE E JOSLIN · 2011 to 2026
$6.7M
NEI NIH HHS K12 EY021475
6 · The paper itself

Abstract

purposeThe aim of this study is to report the short-term efficacy of aflibercept in the treatment of neovascular age-related macular degeneration (AMD) with associated retinal pigment epithelial detachment (PED) which is refractory or develops tachyphylaxis to bevacizumab and ranibizumab.

methodsThe method comprised a retrospective review of the medical records of patients with neovascular AMD and associated PEDs recently treated with aflibercept and previously treated with bevacizumab and ranibizumab.

resultsThree eyes of three female patients of ages 49, 55, and 65 years old with large serous PEDs and subretinal fluid (SRF) associated with occult choroidal neovascularization and neovascular AMD were treated with aflibercept after intravitreal bevacizumab and/or ranibizumab failed to resolve the lesions. All had complete resolution of SRF and complete or near-complete resolution of the PEDs after aflibercept injections over a 3-month period. Visual acuity improved in all three eyes.

conclusionIntravitreal aflibercept may be an effective treatment option for serous PED in neovascular AMD patients after bevacizumab and ranibizumab have previously failed. Larger studies with longer follow-up are required to determine the role of aflibercept in treatment of PED in neovascular AMD.

Indexed as

AgedAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedBevacizumabChoroidal NeovascularizationFemaleHumansIntravitreal InjectionsMacular DegenerationMiddle AgedRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetinal DetachmentRetrospective StudiesTreatment FailureafliberceptAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedBevacizumabRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion Proteins

Identifiers

PMID23558214
PMCPMC3650278
OpenAlexW1997375453

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.